Fenebrutinib, Genentech’s investigational BTK inhibitor, was found to significantly reduce relapse rates compared with the approved therapy Aubagio (teriflunomide) in two Phase 3 clinical trials involving people with relapsing forms of multiple sclerosis (MS). Positive top-line results from one of those trials, FENhance 2 (NCT04586023),…
fenebrutinib
The investigational BTK inhibitor fenebrutinib was as effective as the approved therapy Ocrevus (ocrelizumab) at reducing the risk of disability progression in people with primary progressive multiple sclerosis (PPMS), meeting the main goal of a Phase 3 trial. According to fenebrutinib’s developer, Genentech, the therapy is the…
Recommended Posts
- I regained the confidence to travel after my MS diagnosis
- Common anti-aging drugs may damage brain’s protective coating
- My MS diagnosis opened a window to a whole new world
- Close relatives of MS patients face 100 times higher risk of developing disorder
- Coping with MS means sometimes being inattentive to myself and others